ZA9510865B - Stable 2-chloro-2'-deoxyadenosine formulations - Google Patents

Stable 2-chloro-2'-deoxyadenosine formulations

Info

Publication number
ZA9510865B
ZA9510865B ZA9510865A ZA9510865A ZA9510865B ZA 9510865 B ZA9510865 B ZA 9510865B ZA 9510865 A ZA9510865 A ZA 9510865A ZA 9510865 A ZA9510865 A ZA 9510865A ZA 9510865 B ZA9510865 B ZA 9510865B
Authority
ZA
South Africa
Prior art keywords
formulations
deoxyadenosine
chloro
stable
cda
Prior art date
Application number
ZA9510865A
Other languages
English (en)
Inventor
Michael Bornstein
Kevin Francis Long
Rosemary Rozman
Hsiao Yung Guh
Original Assignee
Ortho Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Pharma Corp filed Critical Ortho Pharma Corp
Publication of ZA9510865B publication Critical patent/ZA9510865B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA9510865A 1994-12-21 1995-12-20 Stable 2-chloro-2'-deoxyadenosine formulations ZA9510865B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/362,106 US5641757A (en) 1994-12-21 1994-12-21 Stable 2-chloro-2'-deoxyadenosine formulations

Publications (1)

Publication Number Publication Date
ZA9510865B true ZA9510865B (en) 1997-06-20

Family

ID=23424722

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9510865A ZA9510865B (en) 1994-12-21 1995-12-20 Stable 2-chloro-2'-deoxyadenosine formulations

Country Status (16)

Country Link
US (1) US5641757A (de)
EP (1) EP0799046B1 (de)
JP (1) JP2001520627A (de)
AT (1) ATE218351T1 (de)
AU (1) AU709785B2 (de)
CZ (1) CZ194197A3 (de)
DE (1) DE69526970T2 (de)
DK (1) DK0799046T3 (de)
ES (1) ES2177677T3 (de)
HU (1) HU220628B1 (de)
IL (1) IL116468A0 (de)
PL (1) PL320918A1 (de)
PT (1) PT799046E (de)
SI (1) SI0799046T1 (de)
WO (1) WO1996019229A1 (de)
ZA (1) ZA9510865B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
SG160391A1 (en) 2004-12-22 2010-04-29 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
US9925151B2 (en) 2006-05-24 2018-03-27 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
JP2012176899A (ja) * 2009-05-19 2012-09-13 Mitsubishi Tanabe Pharma Corp ２−（１−ピペラジニル）−５−メチルベンゼンスルホン酸誘導体を含む注射用水溶液
EP2343074A1 (de) 2009-12-23 2011-07-13 Merck Serono S.A. Verwendung von Purinanaloga zur Behandlung von Atemwegserkrankungen
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
EP3080149A1 (de) 2013-12-13 2016-10-19 Sanofi Duale glp-1-/glucagon-rezeptoragonisten
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
BR112020010282A2 (pt) 2017-11-24 2020-11-17 Merck Patent Gmbh regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla
JP2023541877A (ja) 2020-09-10 2023-10-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫障害の処置のための新規の処置レジメン
EP4302091A1 (de) 2021-03-03 2024-01-10 Ares Trading S.A. Verbesserte behandlungsverfahren mit dmds zur behandlung von autoimmunerkrankungen und biomarker zur vorhersage und/oder optimierung dieser behandlungsverfahren

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US4719295A (en) * 1985-12-31 1988-01-12 Warner-Lambert Company Compound 2-iodo-2'-deoxyadenosine
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
WO1993023058A1 (en) * 1992-05-19 1993-11-25 The Scripps Research Institute Use of 2-halo adenine derivatives as therapeutic agents against chronic myelogenous leukemia

Also Published As

Publication number Publication date
EP0799046B1 (de) 2002-06-05
ES2177677T3 (es) 2002-12-16
JP2001520627A (ja) 2001-10-30
CZ194197A3 (en) 1997-10-15
ATE218351T1 (de) 2002-06-15
HUP9900774A2 (en) 2001-05-28
SI0799046T1 (en) 2002-10-31
WO1996019229A1 (en) 1996-06-27
MX9704731A (es) 1997-10-31
PT799046E (pt) 2002-10-31
EP0799046A1 (de) 1997-10-08
US5641757A (en) 1997-06-24
AU709785B2 (en) 1999-09-09
IL116468A0 (en) 1996-03-31
HU220628B1 (hu) 2002-03-28
AU4422996A (en) 1996-07-10
DE69526970T2 (de) 2003-01-09
PL320918A1 (en) 1997-11-10
DK0799046T3 (da) 2002-09-16
DE69526970D1 (de) 2002-07-11

Similar Documents

Publication Publication Date Title
ZA9510865B (en) Stable 2-chloro-2'-deoxyadenosine formulations
BR9713866A (pt) Composição farmacéutica
MY121360A (en) Clear cleansing detergent systems.
EP0841936A4 (de) Konjugationsstabilisierte therapeutische agenz-zusammensetzungen, formulierungen zur zugabe und diagnostik
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ATE257014T1 (de) Lichtbilderzeugungskontrastmitteln
DE69638351D1 (de) Sowie zur resektion des distalen und vorderen femurs
PL322175A1 (en) Oral pharmaceutic administration forms containing the protonic pump inhibitor and either an acid neutralising agent or alginate
ITTO950085V0 (it) "raccordo luer-lock con cappuccio di protezione per linee medicali di infusione-trasfusione."
CA2151774A1 (en) Skin Disinfecting Formulations
TR199600498A2 (tr) S(+)-ibuprofen'in oral formülasyonlari.
HK1018396A1 (en) Delivery system of an active agent.
DK0886474T4 (da) Karameller indeholdende et södemiddel
TR199600499A2 (tr) S(+)-Etodolak'in oral formülasyonlari.
HK1029290A1 (en) Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions.
ZA9510924B (en) Soluble 2-chloro-2'-deoxyadenosine formulations
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
JO1908B1 (en) Static compounds of 2-chloro-2-dioxin adenosine
IL126998A (en) Potassium, sodium or tris oxaprozin salt pharmaceutical formulations
CA2208241A1 (en) Stable solutions of 2-chloro-2'-deoxyadenosine formulations
ES2178200T3 (es) Conservante para lentes de contacto, solido y soluble en agua.
JO1907B1 (en) Dissolved compounds of 2-chloro-2-dioxin adenosine
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.
EP0612809A3 (en) Compatibilized blends of ppe/polyethylene copolymer.
日合弘 et al. Induction of B-cell Lymphoma in BALB/c nude mice with an ecotropic, B-tropic helper virus present in the MAIDS virus stock.